These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 16899108)

  • 41. Tocilizumab does not block interleukin-6 (IL-6) signaling in murine cells.
    Lokau J; Kleinegger F; Garbers Y; Waetzig GH; Grötzinger J; Rose-John S; Haybaeck J; Garbers C
    PLoS One; 2020; 15(5):e0232612. PubMed ID: 32365119
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Blockade of interleukin 6 signaling induces marked neutropenia in patients with rheumatoid arthritis.
    Nakamura I; Omata Y; Naito M; Ito K
    J Rheumatol; 2009 Feb; 36(2):459-60. PubMed ID: 19208585
    [No Abstract]   [Full Text] [Related]  

  • 43. [Autoimmune aspects of treatment with TNF-alpha inhibitors].
    Kolarz B; Targońska-Stepniak B; Darmochwał-Kolarz D; Majdan M
    Postepy Hig Med Dosw (Online); 2007 Aug; 61():478-84. PubMed ID: 17786135
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Biotechnological drugs: the breakthrough in autoimmune rheumatic conditions.
    Cavagna L; Saketkoo LA; Schwarting A; Caporali R
    Biomed Res Int; 2014; 2014():481973. PubMed ID: 25180183
    [No Abstract]   [Full Text] [Related]  

  • 45. Interleukin-6: Biology, signaling and strategies of blockade.
    Schaper F; Rose-John S
    Cytokine Growth Factor Rev; 2015 Oct; 26(5):475-87. PubMed ID: 26189695
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Interleukin-6 in pathogenesis of rheumatoid arthritis].
    Mihara M; Nishimoto N
    Nihon Rinsho; 2005 Jan; 63 Suppl 1():158-62. PubMed ID: 15799337
    [No Abstract]   [Full Text] [Related]  

  • 47. Immunotherapeutic Interleukin-6 or Interleukin-6 Receptor Blockade in Cancer: Challenges and Opportunities.
    Kampan NC; Xiang SD; McNally OM; Stephens AN; Quinn MA; Plebanski M
    Curr Med Chem; 2018; 25(36):4785-4806. PubMed ID: 28707587
    [TBL] [Abstract][Full Text] [Related]  

  • 48. At the horizon of innovative therapy in rheumatology: new biologic agents.
    Finckh A; Gabay C
    Curr Opin Rheumatol; 2008 May; 20(3):269-75. PubMed ID: 18388517
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Although IL-6 trans-signaling is sufficient to drive local immune responses, classical IL-6 signaling is obligate for the induction of T cell-mediated autoimmunity.
    Lissilaa R; Buatois V; Magistrelli G; Williams AS; Jones GW; Herren S; Shang L; Malinge P; Guilhot F; Chatel L; Hatterer E; Jones SA; Kosco-Vilbois MH; Ferlin WG
    J Immunol; 2010 Nov; 185(9):5512-21. PubMed ID: 20870936
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Rituximab in rheumatic diseases.
    Saraux A; Devauchelle V; Jousse S; Youinou P
    Joint Bone Spine; 2007 Jan; 74(1):4-6. PubMed ID: 17178461
    [No Abstract]   [Full Text] [Related]  

  • 51. Targeted therapy in rheumatoid arthritis.
    Köller MD
    Wien Med Wochenschr; 2006 Jan; 156(1-2):53-60. PubMed ID: 16465614
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Major role of the soluble interleukin-6/interleukin-6 receptor complex for the proliferation of interleukin-6-dependent human myeloma cell lines.
    Gaillard JP; Liautard J; Klein B; Brochier J
    Eur J Immunol; 1997 Dec; 27(12):3332-40. PubMed ID: 9464821
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Interleukin-6 and its receptors: a highly regulated and dynamic system.
    Wolf J; Rose-John S; Garbers C
    Cytokine; 2014 Nov; 70(1):11-20. PubMed ID: 24986424
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Safety of tumour necrosis factor and interleukin-1 blocking agents in rheumatic diseases.
    Botsios C
    Autoimmun Rev; 2005 Mar; 4(3):162-70. PubMed ID: 15823502
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Interleukin-6 and chronic inflammation.
    Gabay C
    Arthritis Res Ther; 2006; 8 Suppl 2(Suppl 2):S3. PubMed ID: 16899107
    [TBL] [Abstract][Full Text] [Related]  

  • 56. mAbs in nonlupus autoimmune rheumatic disease.
    Whelan BR; Isenberg DA
    Curr Opin Hematol; 2009 Jul; 16(4):280-4. PubMed ID: 19444098
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Establishment of a new interleukin-6 (IL-6) receptor inhibitor applicable to the gene therapy for IL-6-dependent tumor.
    Yoshio-Hoshino N; Adachi Y; Aoki C; Pereboev A; Curiel DT; Nishimoto N
    Cancer Res; 2007 Feb; 67(3):871-5. PubMed ID: 17283116
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Targeting IL-6 in the treatment of inflammatory and autoimmune diseases.
    Ding C; Cicuttini F; Li J; Jones G
    Expert Opin Investig Drugs; 2009 Oct; 18(10):1457-66. PubMed ID: 19715447
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [New therapeutic strategy for autoimmune and chronic inflammatory disease based on clinical results using IL-6 blocking therapy with a humanized anti-IL-6 receptor antibody].
    Yoshizaki K
    Yakugaku Zasshi; 2009 Jun; 129(6):667-74. PubMed ID: 19483409
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody.
    Yoshizaki K; Nishimoto N; Mihara M; Kishimoto T
    Springer Semin Immunopathol; 1998; 20(1-2):247-59. PubMed ID: 9836380
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.